Agoracom: Small Cap Investment - Zenith Epigenetics - ZEN-3694 presentation at 28th EORTC-NCI-AACR SYMPOSIUM

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

ZEN-3694 presentation at 28th EORTC-NCI-AACR SYMPOSIUM

posted on Oct 03, 2016 12:39PM

28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics will take place in Munich, Germany from 29 November to 2 December, 2016.

Poster# P089; Abstract #263

The investigational drug ZEN-3694, a novel BET-bromodomain inhibitor, inhibits multiple tumor immune escape mechanisms and has the potential to combine with immunotherapies

S. Attwell, K. Norek, R. Jahagirdar, C. Calosing, S. Lakhotia, E. Campeau, H. Hansen

3 Recommendations

Reply New Message

Back To Forum List View

Please to post a reply